clinical trials

News

Boehringer drug for brain fog in schizophrenia fails trial

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

R&D

Partner Content

Register Now for the AAPS National Biotechnology Conference

The AAPS National Biotechnology Conference uncovers the trends driving today’s biotech markets.

News

Keros pulls study of Winrevair rival after safety signal

Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.

News

Sling shoots at thyroid eye disease with its oral therapy

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.

News

Bayer gains ground in two-fronted Parkinson's offensive

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

R&D

The intricacies of effectively transitioning active clinical...

European Union lawmakers designed EU Clinical Trial Regulation 536/2014 to heighten interest within the healthcare industry for planning and conducting clinical trials in the

Boehringer drug for brain fog in schizophrenia fails trial

Register Now for the AAPS National Biotechnology Conference

Keros pulls study of Winrevair rival after safety signal

Sling shoots at thyroid eye disease with its oral therapy

Bayer gains ground in two-fronted Parkinson's offensive

The intricacies of effectively transitioning active clinical...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks